Chloroquine and Hydroxychloroquine is an antimalarial, disease-modifying anti-rheumatic drug. In China and France, some studies provided some indications of possible benefits against pneumonia caused by COVID-19 but need confirmation through randomized trials.
There are many trials going on now to test the efficacy of these drugs. Mechanism of action of hydroxychloroquine includes multiple effects including reduced cytokine production, inhibits immune activation and also interferes with lysosomal activity and membrane stability.
Chloroquine was discovered in 1934 by Hans AndersagIt is usually available as a generic medication. Common side effects include muscle problems, loss of appetite, diarrhoea, and skin rash and serious side effects include problems with vision, muscle damage, seizures, and low blood cell levels. It is a member of the drug class 4-aminoquinoline.
During pregnancy, a woman undergoes with multiple interactions with the health care system that increases her chance of getting infected. So therefore, managing pregnant population presents a unique challenge during COVID-19. The physiological changes and partial immune suppression during pregnancy makes pregnant women and new-born babies susceptible to several infections. Post-partum haemorrhage, maternal sepsis, preeclampsia, and premature rupture of membrane are the most common COVID-19-induced adverse events reported among pregnant women.
Important Alert:
X
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Photodegradation of two pharmaceutical namely levofloxacin and atorvastatin via Chitosan/Ag/TiO2 3D printed scaffold
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Preparation and characterization of fibers crafted from PCL/PVP-ChAgG, coupled with investigating their suitability as wound dressings.
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Is your drug delivery formulation harming the environment ? Approaches to both save human health and the environment
Thomas J. Webster, Mansfield Bioincubator, United States
Title : Unveiling the binding interactions of selected antimalarial drugs with major plasma transporter
Saad Tayyab, UCSI University, Malaysia
Title : Pharmacokinetic properties of TNX-102 SL, a sublingual formulation of cyclobenzaprine hydrochloride
Bruce Daugherty, Tonix Pharmaceuticals, United States
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Mannitol as eutectic forming agent for improved sublingual delivery of Cyclobenzaprine HCl
Marino Nebuloni, University of Insubria, Italy